Switching to an IBD Biosimilar: Patient Perspective

DEBATE: Biosimilar Therapies - Caution, more studies are neededПодробнее

Incorporating IBD Biosimilars into Practice: Patient Care and EducationПодробнее

Switching to biosimilar medicationsПодробнее

Biosimilars for IBD: When to Start, Switch, or Stay Away?Подробнее

Switching to an IBD Biosimilar: Caregiver PerspectiveПодробнее

Biosimilars for IBD: Start, Switch, or Stay Away?Подробнее

IBD: Switching from a Biologic to a BiosimilarПодробнее

Patient and Provider Perspectives for Biosimilars in IBD and RA - Is Similar the Same?Подробнее

Biosimilars for IBD: To Start, Switch, or Stay Away?Подробнее

What to Know Before Switching from Biologics to Biosimilars?Подробнее

Why IBD Patients Should Know About BiosimilarsПодробнее

Making the Switch from Biologics to Biosimilars in IBD: Knowledge Over SkepticismПодробнее

Understanding biosimilars: what IBD patients & caregivers need to knowПодробнее

Switching from a Biologic to Biosimilar Drug for IBD in OntarioПодробнее

Understanding Biosimilars - What IBD Patients Should KnowПодробнее

Switching to Biosimilars 2021Подробнее

Understanding Biosimilars - For IBD PatientsПодробнее

Biosimilars and Inflammatory Bowel DiseaseПодробнее

IBD Clinical Case: The Process of Switching from a Reference Biologic to a BiosimilarПодробнее

Patient Care in IBD: Incorporating Biosimilars into Clinical PracticeПодробнее

Biosimilars for IBD: Making the Transition WebinarПодробнее